RxDoctor Payments Data

Christopher Dressel, MD

Interventional Cardiology · Scranton, PANPI 1598760928

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.2% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Boston Scientific at 29.0% of the total. Reporting peaked in 2022 at $695 and has fallen 97.7% since, to $16 in 2025. That places this record below the midpoint for interventional cardiology clinicians in PA, where the typical reported total is $6,486.

$1,673in general payments, 2019–2025

Across 43 payments — averaging $38.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$485
  • E.r. Squibb & Sons, L.L.C.$437
  • Edwards Lifesciences$310
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$103
  • Boehringer Ingelheim$95
  • Abbott$78
  • plus $165 from 5 others

What the payments were for

  • Food & beverage$1,65999%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,673 in reported general payments places this provider in the 15th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024
$47,316
Medicare patients
491
Services billed
777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban176$199,223
EntrestoSacubitril/Valsartan33$39,375
XareltoRivaroxaban23$31,246
Metoprolol Succinate199$2,906
Atorvastatin Calcium263$2,649
Diltiazem 12hr ErDiltiazem Hcl21$1,612
Diltiazem 24hr Er (Cd)Diltiazem Hcl44$940
Rosuvastatin Calcium61$908
Potassium Chloride22$834
ClopidogrelClopidogrel Bisulfate53$738
Metoprolol Tartrate99$618
Lisinopril86$563
Losartan Potassium35$479
Warfarin Sodium33$472
Ezetimibe21$471

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Scranton

See the full list for Pennsylvania →

Where these figures come from

Is this you, or does something look wrong? →